Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014:357027.

Sacha T. Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis. 2014;6(1): e2014007. https://doi.org/10.4084/MJHID.2014.007.

Article  PubMed  PubMed Central  Google Scholar 

Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110(8):2828–37. https://doi.org/10.1182/blood-2007-04-038943.

Article  CAS  PubMed  Google Scholar 

Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879–94. https://doi.org/10.2165/00003088-200544090-00001.

Article  CAS  PubMed  Google Scholar 

Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making. Curr Hematol Malig Rep. 2018;13(3):202–11. https://doi.org/10.1007/s11899-018-0449-7.

Article  PubMed  PubMed Central  Google Scholar 

Récoché I, Rousseau V, Bourrel R, et al. Drug-drug interactions with imatinib: an observational study. Medicine. 2016;95(40): e5076. https://doi.org/10.1097/MD.0000000000005076.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson JR, Bross P, Cohen M, et al. Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res. 2003;9(6):1972–9.

CAS  PubMed  Google Scholar 

Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biol. 2010;4:315–23. https://doi.org/10.2147/BTT.S5775.

Article  CAS  Google Scholar 

Atallah E, Durand J, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–7. https://doi.org/10.1182/blood-2007-01-070144.

Article  CAS  PubMed  Google Scholar 

Dhalluin-Venier V, Besson C, Dimet S, et al. Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2006;18(11):1235–7. https://doi.org/10.1097/01meg.0000243867.56454.13.

Article  CAS  PubMed  Google Scholar 

Al Sobhi E, Zahrani Z, Zevallos E, et al. Imatinib-induced immune hepatitis: case report and literature review. J Hematol. 2007;12(1):49–53. https://doi.org/10.1080/10245330600937929.

Article  Google Scholar 

Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arc Pathol Lab Med. 2015;139(7):876–87. https://doi.org/10.5858/arpa.2014-0214-RA.

Article  CAS  Google Scholar 

Gleevec® (imatinib mesylate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s060lbl.pdf. Accessed 5 Dec 2023

Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Safe. 2013;36(7):491–503. https://doi.org/10.1007/s40264-013-0048-4.

Article  CAS  Google Scholar 

Wang Z, Wang X, Wang Z, et al. Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(7): e2120165. https://doi.org/10.1001/jamanetworkopen.2021.20165.

Article  PubMed  PubMed Central  Google Scholar 

Steegmann JL, Baccarani M, Breccia M, et al. European Leukaemia Net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukaemia. 2016;30(8):1648–71. https://doi.org/10.1038/leu.2016.104.

Article  CAS  Google Scholar 

Kim TD, Schwarz M, Nogai H, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20(11):129–1214. https://doi.org/10.1089/thy.2010.0251.

Article  CAS  Google Scholar 

de Groot J, Zonnenberg BA, Plukker J, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharm Therap. 2005;78(4):433–8. https://doi.org/10.1016/j.clpt.2005.06.010.

Article  CAS  PubMed  Google Scholar 

MacLure K, Tobaiqy M, Stewart D. Imatinib associated with hepatic and thyroid toxicity: A systematic review. 2019. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019121359 Accessed 5 Sep 2023

MacLure K, Paudyal V, Stewart D. Reviewing the literature, how systematic is systematic? Int J Clin Pharm. 2016;38(3):685–94. https://doi.org/10.1007/s11096-016-0288-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P): elaboration and explanation. BMJ. 2015;349: g7647. https://doi.org/10.1136/bmj.g7647.

Article  Google Scholar 

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. https://doi.org/10.1016/0197-2456(95)00134-4.

Article  CAS  PubMed  Google Scholar 

Hartling L, Milne A, Hamm MP, et al. Testing the newcastle ottawa scale showed low reliability between individual reviewers. J Clin Epidemiol. 2013;66(9):982–93. https://doi.org/10.1016/j.jclinepi.2013.03.003.

Article  PubMed  Google Scholar 

Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ EBM. 2018;23(2):60–3. https://doi.org/10.1136/bmjebm-2017-110853.

Article  Google Scholar 

Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, et al. The value of case reports in systematic reviews from rare diseases. The example of enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis type II (MPS-II). Int J Environ Res Public Health. 2020;17(18):6590. https://doi.org/10.3390/ijerph17186590.

Article  PubMed  PubMed Central  Google Scholar 

Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–7. https://doi.org/10.1200/JCO.2017.74.7162.

Article  CAS  PubMed  Google Scholar 

Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. NEJM. 2017;376(10):917–27. https://doi.org/10.1056/NEJMoa1609324.

Article  CAS  PubMed  Google Scholar 

O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. NEJM. 2003;348(11):994–1004. https://doi.org/10.1056/NEJMoa022457.

Article  CAS  PubMed  Google Scholar 

Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. NEJM. 2006;355(23):2408–17. https://doi.org/10.1056/NEJMoa062867.

Article  CAS  PubMed  Google Scholar 

Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial. Leukemia. 2022;36(7):1825–33. https://doi.org/10.1038/s41375-022-01589-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian H, Shah NP, Shah S, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. NEJM. 2010;362(24):2260–70. https://doi.org/10.1056/NEJMoa1002315.

Article  CAS  PubMed  Google Scholar 

Saglio G, Kim D, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEJM. 2010;362(24):2251–9. https://doi.org/10.1056/NEJMoa0912614.

Article  CAS  PubMed  Google Scholar 

Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54. https://doi.org/10.1038/leu.2016.5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. https://doi.org/10.1200/JCO.2015.64.8899.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petzer AL, Wolf D, Gercheva L, et al. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: First results from the randomized CELSG phase III CML 11 “ISTAHIT” study. Haematologica. 2010;95(6):908–13. https://doi.org/10.3324/haematol.2009.013979.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes JE, Kim D, Gambacorti-Passerini C, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486–92. https://doi.org/10.1200/JCO.2011.38.7522.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Preudhomme C, Guilhot F, Guilhot J, et al. Imatinib pl